-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The term "involution" is mainly used to describe the occurrence of irrational internal competition in a certain field.
Among them, in the field of anti-tumor drugs, the "involution" of PD-1 is increasing in recent years
.
In China, multinational pharmaceutical companies Merck’s K drug, Bristol-Myers Squibb’s O drug, Roche’s T drug, and Pfizer’s B drug entered the domestic market as early as 2018, and subsequently treated Hodgkin’s lymphoma in December 2018.
After China's first domestically produced PD-1 antibody drug Sintilizumab injection was approved for marketing, it means that anti-tumor immunotherapy has entered the "China Innovation Era"
.
In recent years, domestic PD-1 market competition has become more and more fierce.
At present, there are as many as 6 domestically-made PD-1 listed in China, namely Hengrui's Karelizumab and BeiGene's Tielelizumab.
, Cinda Bio-Sintilimab, Junshi Bio-Treplimumab, Kangfang Bio-Bio's Paimrizumab and Yuheng Bio-Sepalimumab, the last two of which are 2021 Newly approved products, and the first four models have entered medical insurance through price cuts, PD-1 has also entered the era of "annual fee of 10,000 yuan"
.
The newly-listed Kangfang Bio/CP Tianqing's Paimrizumab also reduced its annual cost to 19,500 yuan per year under conditions such as charity donations
.
According to a Southwest Securities research report, as of February 2021, there are 154 PD-1 monoclonal antibodies under development worldwide, of which 8 have been listed, 5 are in the application for listing stage, and 7 are in the phase III clinical stage
.
It is estimated that in the next 2 to 3 years, there will be more than 20 PD-1 products on the market worldwide
.
The research and development of PD-1 in China is very hot.
Among the 154 PD-1s in the world, 85 are researched or developed jointly by Chinese companies, accounting for 55%
.
In addition, from the domestic situation of PD-1 monoclonal antibody, in addition to the 6 products approved for marketing, 3 products are still in the market application stage, and 7 are in the phase III clinical stage.
It is expected that in the future 2~3 The number of PD-1 monoclonal antibodies on the domestic market will reach 15
.
It can be said that the "involution" of PD-1 is intensifying, and the industry believes that in the future, companies will fight for two major capabilities.
.
One is the indications.
According to incomplete statistics, among the current domestic PD-1 monoclonal antibodies for tumor indications, carrelizumab has as many as six indications; and for indications involving first-line treatment, tisolali There are two types of benzumab
.
In addition to the existing indications, there are other tumor indications for domestic PD-1 products that are being submitted or entering the clinical stage
.
For example, Cinda Biosciences has a total of 23 domestic R&D pipelines, of which 7 indications have entered phase 3 clinical trials; while in overseas R&D pipelines, BeiGene has 11 in total
.
In addition, on the evening of September 1st, Junshi Biologics' Teriplimumab has submitted a registration application to the US FDA.
The indication is nasopharyngeal carcinoma, which is mainly single-agent third-line treatment
.
In general, the indications of domestic PD-1 are showing a state of intensive research and development, including lung cancer, gastric cancer, liver cancer, esophageal cancer, etc.
, each indication has more than 10 under research
.
The second is commercialization capabilities.
In addition to the advantages of continuous approval for indications, companies also need to make corresponding arrangements quickly in order to occupy the market
.
Among them, in the domestic market, domestic PD-1 wants to further expand the market, it needs to develop the primary medical market and PD-1-based drug combination therapy, but with the advancement of medical insurance, PD-1 may continue to innovate in the future Low price
.
In foreign markets, "going abroad" is a layout strategy adopted by many companies
.
It is understood that 5 PD-1 pharmaceutical companies, including Cinda Biotech and BeiGene, have all been authorized overseas
.
As early as 2017, Yuheng Pharmaceutical/WuXi Biologics's Sepalizumab has been authorized overseas
.
Among them, in the field of anti-tumor drugs, the "involution" of PD-1 is increasing in recent years
.
In China, multinational pharmaceutical companies Merck’s K drug, Bristol-Myers Squibb’s O drug, Roche’s T drug, and Pfizer’s B drug entered the domestic market as early as 2018, and subsequently treated Hodgkin’s lymphoma in December 2018.
After China's first domestically produced PD-1 antibody drug Sintilizumab injection was approved for marketing, it means that anti-tumor immunotherapy has entered the "China Innovation Era"
.
In recent years, domestic PD-1 market competition has become more and more fierce.
At present, there are as many as 6 domestically-made PD-1 listed in China, namely Hengrui's Karelizumab and BeiGene's Tielelizumab.
, Cinda Bio-Sintilimab, Junshi Bio-Treplimumab, Kangfang Bio-Bio's Paimrizumab and Yuheng Bio-Sepalimumab, the last two of which are 2021 Newly approved products, and the first four models have entered medical insurance through price cuts, PD-1 has also entered the era of "annual fee of 10,000 yuan"
.
The newly-listed Kangfang Bio/CP Tianqing's Paimrizumab also reduced its annual cost to 19,500 yuan per year under conditions such as charity donations
.
According to a Southwest Securities research report, as of February 2021, there are 154 PD-1 monoclonal antibodies under development worldwide, of which 8 have been listed, 5 are in the application for listing stage, and 7 are in the phase III clinical stage
.
It is estimated that in the next 2 to 3 years, there will be more than 20 PD-1 products on the market worldwide
.
The research and development of PD-1 in China is very hot.
Among the 154 PD-1s in the world, 85 are researched or developed jointly by Chinese companies, accounting for 55%
.
In addition, from the domestic situation of PD-1 monoclonal antibody, in addition to the 6 products approved for marketing, 3 products are still in the market application stage, and 7 are in the phase III clinical stage.
It is expected that in the future 2~3 The number of PD-1 monoclonal antibodies on the domestic market will reach 15
.
It can be said that the "involution" of PD-1 is intensifying, and the industry believes that in the future, companies will fight for two major capabilities.
.
One is the indications.
According to incomplete statistics, among the current domestic PD-1 monoclonal antibodies for tumor indications, carrelizumab has as many as six indications; and for indications involving first-line treatment, tisolali There are two types of benzumab
.
In addition to the existing indications, there are other tumor indications for domestic PD-1 products that are being submitted or entering the clinical stage
.
For example, Cinda Biosciences has a total of 23 domestic R&D pipelines, of which 7 indications have entered phase 3 clinical trials; while in overseas R&D pipelines, BeiGene has 11 in total
.
In addition, on the evening of September 1st, Junshi Biologics' Teriplimumab has submitted a registration application to the US FDA.
The indication is nasopharyngeal carcinoma, which is mainly single-agent third-line treatment
.
In general, the indications of domestic PD-1 are showing a state of intensive research and development, including lung cancer, gastric cancer, liver cancer, esophageal cancer, etc.
, each indication has more than 10 under research
.
The second is commercialization capabilities.
In addition to the advantages of continuous approval for indications, companies also need to make corresponding arrangements quickly in order to occupy the market
.
Among them, in the domestic market, domestic PD-1 wants to further expand the market, it needs to develop the primary medical market and PD-1-based drug combination therapy, but with the advancement of medical insurance, PD-1 may continue to innovate in the future Low price
.
In foreign markets, "going abroad" is a layout strategy adopted by many companies
.
It is understood that 5 PD-1 pharmaceutical companies, including Cinda Biotech and BeiGene, have all been authorized overseas
.
As early as 2017, Yuheng Pharmaceutical/WuXi Biologics's Sepalizumab has been authorized overseas
.
